Anavex Life Sciences (AVXL) is a publicly traded Healthcare sector company. As of July 21, 2026, AVXL trades at $2.57 with a market cap of $221.49M and a P/E ratio of -5.25. AVXL moved +3.93% today. Year to date, AVXL is -36.32%; over the trailing twelve months it is -77.96%. Its 52-week range spans $2.26 to $14.44. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces AVXL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for AVXL, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $2.57 |
| Market Cap | $221.49M |
| P/E Ratio | -5.25 |
| EPS | $-0.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.44 |
| 52-Week Low | $2.26 |
| Volume | 363.58K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.36M |
| Net Income | $-39.95M |
| Gross Margin | 0.00% |
1 analysts cover AVXL: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.